|
|
|
Market Research Report
The Top 10 World's Leading Life Science Intermediate Companies: DSM
| Published by |
Venture Planning Group |
|
| Published |
2006/06 |
Content info |
Pages: 76 |
| Product code |
57823 |
| Price |
From US $ 1250  |
|
|
PDF by E-Mail Approx. 1-2 business days
Hard Copy/CD-ROM Approx. 3-4 business days
If you need expedited delivery, please call us.
|
|
Table of Contents
SECTION I. EXECUTIVE SUMMARY
- A 3-5 page synopsis of main sections.
SECTION II. BUSINESS ORGANIZATION
- History of the life science intermediates business evolution, important to
the understanding of the corporate culture, management mentality and
strategies.
- Recent acquisitions, divestitures and significant organizational changes.
- Current organizational structure.
SECTION III. SENIOR MANAGEMENT
- Background of key executives.
SECTION IV. FACILITIES AND EMPLOYEES
- Major administrative, manufacturing and R&D facilities in the U.S. and
abroad.
- New plants under construction.
- U.S. and international work force size and distribution.
SECTION V.TECHNOLOGICAL KNOW-HOW
- Internally developed and acquired technologies, and related capabilities.
- Proprietary technologies and patent litigations.
SECTION VI. PRODUCT PORTFOLIO
- Extensive review of major product lines.
SECTION VII. MARKETING TACTICS
- Major promotional strategies.
- Distribution approaches.
- Product service and support.
SECTION VIII. FINANCIAL ANALYSIS
- Sales and operating profit by division, product line, geographic region
and country.
- Five-year sales and profit performance.
SECTION IX. R&D EXPENDITURES AND MAJOR PROGRAMS
- Estimated R&D budget.
- Research facilities and staff.
- New technologies, products and applications in development.
SECTION X. COLLABORATIVE ARRANGEMENTS
- Major joint venture, distribution, OEM and licensing partners, both
industrial and academic.
- Terms of collaborative agreements and specific products involved.
SECTION XI. STRATEGIC DIRECTION
- Specific business, new product development and marketing strategies.
- Strengths and weaknesses.
- Anticipated acquisitions, joint ventures and divestitures.
|
Related Report
|
|
Please inform me when related publications are released
|